PG-01

• 产品号: P0024
• CAS号: 853138-65-5
• 分子式: C28H29N3O2
• 分子量: 439.54876
• 纯 度: ≥98% (HPLC)

产品别名

• 标题: PG-01
• IUPAC标准名: 2-[2-(1H-indol-3-yl)-N-methylacetamido]-2-phenyl-N-[4-(propan-2-yl)phenyl]acetamide
• IUPAC传统名: 2-[2-(1H-indol-3-yl)-N-methylacetamido]-N-(4-isopropylphenyl)-2-phenylacetamide
• 别名: N-Methyl-N-[2-[[4-(1-methylethyl)phenyl]amino]-2-oxo-1-phenylethyl]-1H-indole-3-acetamide; 2-[(2-1H-indol-3-yl-acetyl)-methylamino]-N-(4-isopropylphenyl)-2-phenylacetamide

产品登记号

• MDL号: MFCD03449821
• CAS号: 853138-65-5

产品性质

• Empirical Formula (Hill Notation): C28H29N3O2
• 纯度: ≥98% (HPLC)
• 外观: white to off-white powder
• 溶解度: DMSO: ≥10 mg/mL
• GHS警示词: Warning
• GHS危险声明: H302-H413
• 欧盟危险性物质标志: 有害性(Harmful) (Xn)
• 危险公开号: 22
• 保存温度: -20°C
• 德国WGK号: 3

产品详细信息

详细说明 (English)

Biochem/physiol Actions
CFTR mutations are responsible for cystic fibrosis. The most common mutation is ΔF508, but many others exist. Drugs which can correct channel function of a broad range of CFTR mutants are most desirable for clinical development. PG-01 is a potentiator of ΔF508 (Ka 70 nM) as well as mutants G551D and G1349D (Ka 1100 and 40 nM, respectively). Its broad spectrum may make it more desirable than more mutant-specific CFTR correctors.

详细说明 (简体中文)

Biochem/physiol Actions
CFTR mutations are responsible for cystic fibrosis. The most common mutation is ΔF508, but many others exist. Drugs which can correct channel function of a broad range of CFTR mutants are most desirable for clinical development. PG-01 is a potentiator of ΔF508 (Ka 70 nM) as well as mutants G551D and G1349D (Ka 1100 and 40 nM, respectively). Its broad spectrum may make it more desirable than more mutant-specific CFTR correctors.